glp-1 agonists for diabetes Study finds GLP-1 receptor agonists

Both medications work through the same GLP-1 pathway

3.3 Long-acting GLP1 receptor agonists: Once-weekly 3.3.1 Semaglutide SMG is an analog of long-acting GLP-1, mainly used to control T2DM, and is also suitable for promoting weight loss in people with mild obesity (95, 96)

Recognizing the need for effective strategies to mitigate these challenges in the postoperative period, anti-obesity pharmacotherapy has emerged as a promising adjunctive approach

Trulicity (dulaglutide) Approved - A weekly GLP-1 receptor agonist for managing type 2 diabetes that also supports moderate weight loss by regulating appetite and blood sugar

The risk of Alzheimers disease was reduced by 24% (HR 0.76

Tirzepatide was approved by the Food and Drug Administration in May 2022 for the treatment of T2D, and later in October received Fast Track designation for treatment of obesity